Skip to main content

Want a detailed portfolio tracker?

CTOR
NASDAQ
$0.57

Citius Oncology Inc (CTOR)

Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies tailored for underserved patient populations. With a robust pipeline of proprietary technologies, Citius aims to enhance treatment efficacy and safety across various cancer indications. The company is strategically advancing its promising drug candidates through pivotal clinical trials and regulatory processes, leveraging partnerships and rigorous clinical research standards to optimize patient outcomes and address critical needs in the oncology sector.
Website: https://citiusonc.com/overview/default.aspx
68 analysts
Strong Buy
Target: $4 (+601.75%)

Market Cap

$64M

Free Cash Flow Yield

-18.34%

Beta (5Y)

-0.10

Price Chart

Valuation
Market Cap$64M
Forward P/E35.59
P/S11.41
P/B1.71
Profitability
Total Revenue (TTM)$5.61M
Gross Profit (TTM)$4.49M
EBITDA-$42M
Operating Margin-1716%
EPS-$0.49
Financial Health
Free Cash Flow Yield-18.34%
Growth & Risk
Beta (5Y)-0.10
Sharpe Ratio-0.79